期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Sample size re-estimation without un-blinding for time-to-event outcomes in oncology clinical trials 被引量:1
1
作者 Lihong Huang Jianling Bai +1 位作者 Hao Yu Feng Chen 《The Journal of Biomedical Research》 CAS CSCD 2018年第1期23-29,共7页
Sample size re-estimation is essential in oncology studies. However, the use of blinded sample size reassessment for survival data has been rarely reported. Based on the density function of the exponential distributio... Sample size re-estimation is essential in oncology studies. However, the use of blinded sample size reassessment for survival data has been rarely reported. Based on the density function of the exponential distribution, an expectation-maximization(EM) algorithm of the hazard ratio was derived, and several simulation studies were used to verify its applications. The method had obvious variation in the hazard ratio estimates and overestimation for the relatively small hazard ratios. Our studies showed that the stability of the EM estimation results directly correlated with the sample size, the convergence of the EM algorithm was impacted by the initial values, and a balanced design produced the best estimates. No reliable blinded sample size re-estimation inference can be made in our studies, but the results provide useful information to steer the practitioners in this field from repeating the same endeavor. 展开更多
关键词 oncology study clinical trial sample size re-estimation expectation-maximization algorithm
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部